Abstract: An electrotransport system for delivery of an electrotransport cationic drug. The system has an anode that has a precipitating anion source. The precipitating anions from the precipitating anion source combines with metal ions generated from sacrificial metal of the anode during electrotransport to form precipitates. Metal that can form the metal ions are embedded in the anode.

Abstract: Electrotransport drug delivery devices, systems and methods for delivery of lofentanil or carfentanil are disclosed. The lofentanil or carfentanil may be provided as a water soluble salt (e.g., lofentanil or carfentanil hydrochloride), such as in a hydrogel formulation. A transdermal, electrotransport delivered dose of lofentanil or carfentanil is provided which is sufficient to induce analgesia in (e.g., adult) human patients suffering from chronic, acute and/or breakthrough pain.

Abstract: A transdermal electrotransport drug delivery system to an individual. The system has a liquid imbibing polymer with carboxyl groups available for noncovalently associating with a cationic drug. The liquid imbibing polymer is applicable for imbibing liquid before the device is deployed on a patient for electrotransport drug delivery.

Abstract: The present invention provides methods and devices for the electrotransport delivery of beneficial agents that utilize polymer electrolyte matrices as drug reservoirs. In certain aspects of the invention, the beneficial agents are hydrolytically unstable, and methods are provided for enhancing the stability of the hydrolytically unstable beneficial agents during long-term storage of devices for the electrotransport delivery of the hydrolytically unstable beneficial agents and during electrotransport delivery of the hydrolytically unstable beneficial agents.

Abstract: A transdermal nicotine salt delivery system to an individual. The system has a high nicotine salt loading to effect therapeutic flux rate. Acrylate polymeric drug reservoir with the high nicotine salt dissolved therein provides desirable adhesive characteristics and effective transdermal therapeutic properties.

Abstract: A cathode for an electrotransport drug delivery system for the delivery of anionic drugs. The cathode has a composite structure that contains an electroactive species that upon reduction does not generate any gas or an anion that competes with the anionic drug during electrotransport.

Abstract: A transdermal electrotransport drug delivery system having reduced potential for abuse. The system uses ion barrier, preferentially ion exchange material to separate the drug from an antagonist and provides for the release of the antagonist with the agonist when the system is subject to abuse.

Abstract: A device for transdermally delivering an anticoagulant agent by electrotransport. Preferably, the anticoagulant comprises a benzamidine or a naphthamidine derivative. A particularly preferred benzamidine derivative is a 2-[3-[4-(4-piperidinyloxy)anilino]-1-propenyl]benzamidine derivative. The devices are configured to maintain a plasma concentration of 20-80 ng/mL or providing a flux in the range of approximately 20-40 mg/day. Suitable current densities include 0.050 and 0.10 mA/cm2. Methods of the invention include delivering the anticoagulants to precisely maintain the desired plasma concentrations. The invention also comprises treating thromboembolic disease and inhibiting Factor Xa.

Abstract: Methods for preparing compositions for use in electrotransport delivery systems. The method includes providing a drug solution comprising drug ions and associated counterions; adjusting the pH of the drug solution by contacting the drug solution with a ion exchange material first; separating the ion exchange material from the pH-adjusted drug solution; and buffering the pH-adjusted drug solution with a buffer. A peptidic buffer is preferably used. The methods result in compositions suitable for use in electrotransport delivery systems.

Abstract: The present invention provides methods for preparing compositions for use in electrotransport delivery systems that comprise providing a drug solution comprising drug ions and associated counterions; adjusting the pH of the drug solution by contacting the drug solution with a first ion exchange material; separating the first ion exchange material from the pH-adjusted drug solution; adding the pH-adjusted drug solution to a reservoir of an electrotransport delivery system; and contacting the pH-adjusted drug solution with a second ion exchange material.

Abstract: Composition of matter for application to a body surface or membrane to administer a N-(2,5-Disubstituted phenyl)-N′-(3-substituted phenyl)-N′-methyl guanidine by permeation through the body surface or membrane, the composition comprising the guanidine compound to be administered, at a therapeutically effective rate, optionally in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices and methods for the transdermal administration of a guanidine for the prevention of neuropathic pain, neuropsychological deficits resulting from cardiac surgery (CABG), and other neurological disorders.

Abstract: Composition of matter for application to a body surface or membrane to administer a N-(2,5-Disubstituted phenyl)-N′-(3-substituted phenyl)-N′-methyl guanidine by permeation through the body surface or membrane, the composition comprising the guanidine compound to be administered, at a therapeutically effective rate, optionally in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices and methods for the transdermal administration of a guanidine for the prevention of neuropathic pain, neuropsychological deficits resulting from cardiac surgery (CABG), and other neurological disorders.

Abstract: Preferential delivery via electrotransport of a preferred isomeric form of a pharmaceutically active chiral compound from a mixture of the isomeric forms of said compound is provided. A method of decreasing the delivery via electrotransport of a less preferred isomer of a drug is also provided. Drug delivery devices suitable for such preferential delivery and methods of making the same are also provided.

Abstract: The electrotransport drug delivery device includes a patient activity sensor which is used to selectively deliver drugs based upon a measured physical activity of the patient.

Abstract: An iontophoresis device including a control module and a disposable electrode module. The control module includes a flexible printed circuit board carrying the battery and other electrical components. The control module is so configured that by trimming it along one of several labeled lines, various current levels may be selected. Trimming the control module provides a simple method for varying the dosage of the drug delivered by the iontophoresis device and simultaneously provides an easily readable visual indicator of the dosage level.